PAX6 and breast carcinoma: And compared with ER-positive and HER2-negative breast cancers without ALNM, the methylation levels of AKR1B1, RASGRF2, CRMP1, BNIP3, GSTP1, HOXA5, and PAX6 promoter were increased in ER-positive and HER2-negative breast cancers with ALNM.